Posted by Michael Wonder on 22 Feb 2021
Clinical relevance of patient-reported outcomes: new threshold proves to be practical
18 February 2021 - Current examples show that the 15% threshold newly set by IQWiG for the recognition of responder analyses in the early benefit assessment of drugs works.
In order to show the clinical relevance of a difference between two treatment alternatives, the submitted manufacturer dossiers have been increasingly containing responder analyses for patient-relevant outcomes as part of the early benefit assessment of new drugs.
